Literature DB >> 29696993

Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.

Yelda Buyru Özkurt1, Sezen Akkaya1, Sibel Aksoy1, Mert Hakan Şimşek2.   

Abstract

PURPOSE: : To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion.
METHODS: : The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time. The patients received an injection or laser treatment at baseline and were, then, retreated as needed and were followed for 12 months. The mean best corrected visual acuity changes over the follow-up and the decrease in the mean central macular thickness were evaluated.
RESULTS: : A total of 27 and 24 patients were assigned to intravitreal ranibizumab and subthreshold micropulse laser subgroups, respectively. The mean number of treatment was 3.81 of intravitreal ranibizumab group and 1.5 of subthreshold micropulse laser group (p < 0.05). The subgroups were similar with regard to the mean score of best corrected visual acuity at baseline, at 1, 6, and 12 months (p > 0.05). The decrease in the mean central macular thickness was significant in both intravitreal ranibizumab and subthreshold micropulse laser groups at 1, 6, and 12 months than that of values at baseline (p < 0.05). No new ocular or systemic adverse events were observed.
CONCLUSION: : Our study results showed that intravitreal ranibizumab or yellow subthreshold micropulse laser treatment for macular edema due to branch retinal vein occlusion was not found to be superior to each other for reducing macular thickness and increasing visual acuity for 1-year period. Based on these results, subthreshold micropulse laser may be a useful alternative approach in the treatment of macular edema secondary to branch retinal vein occlusion.

Entities:  

Keywords:  Branch retinal vein occlusion; macular edema; ranibizumab; subthreshold micropulse laser

Mesh:

Substances:

Year:  2018        PMID: 29696993     DOI: 10.1177/1120672117750056

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  4 in total

1.  Clinical efficacy of conbercept plus micropulse laser (577 nm) treatment in macular edema secondary to non-ischemic central retinal vein occlusion.

Authors:  Li Li; Qian Ren; Zhaohui Sun; Hua Yu
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

Review 2.  Micropulse Laser Treatment of Retinal Diseases.

Authors:  Maciej Gawęcki
Journal:  J Clin Med       Date:  2019-02-13       Impact factor: 4.241

Review 3.  A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion.

Authors:  Juan Lyn Ang; Sarah Ah-Moye; Leah N Kim; Vuong Nguyen; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-04-20       Impact factor: 3.775

4.  The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion: A protocol for systematic review and meta-analysis.

Authors:  Guang Chen; Peng Chen; Xiaoping Chen; Jing Wang; Xinming Peng
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.